▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Michael Douglass

TMFEnterprise

Former Deputy Managing Editor, Fool.com. I started in Healthcare, but you'll find me writing regularly about biotech, dividend stocks, and personal finance.

Recent Articles by Michael Douglass

May 6, 2016 by Michael Douglass

Highlights from Berkshire Hathaway with Industry Focus: Financials

Berkshire Hathaway’s annual meeting is often referred to as “Woodstock for capitalists.” Join us to learn why… from someone who was there!

May 3, 2016 by Michael Douglass

Gilead Sciences Is Cannibalizing Its Own Sales, and Management Loves It

It sounds weird at first, but it makes sense.

May 2, 2016 by Michael Douglass

Good News: Gilead Sciences Discounted Its Drugs Again

More competition means lower prices -- and it's a good thing Gilead recognized that before its hand was forced.

May 1, 2016 by Michael Douglass

Bad News: Your Retirement's Probably Not on Track

A new survey shows just how low confidence is that workers are saving enough for retirement.

May 1, 2016 by Michael Douglass and Kristine Harjes

Does Healthcare’s Past Predict its Future?

Some things never change -- and in healthcare, we sometimes feel like we’re talking about the same stuff year in and year out. Join us as we cover some stories that were a big deal in 2014, check in on how they’re going now, and predict some major trends in 2018.

May 1, 2016 by Michael Douglass

You'll Never Guess the Surprising Way Obamacare Is Helping Millions of Americans (Hint: It Has Nothing to Do With Their Health)

The benefits are startling.

Apr 28, 2016 by Michael Douglass

The Most Important Thing I Hope to Learn from Warren Buffett This Weekend

Berkshire Hathaway's annual meeting is Saturday. Here's why I'm going to Omaha.

Apr 16, 2016 by Michael Douglass

Is Retail Opportunity Investments Corp. Stock a Buy Now?

Solid dividend, growth opportunities, aggressive management -- what's not to like?

Mar 30, 2016 by Michael Douglass

3 Reasons Exact Sciences Stock Could Rise

Three positive indicators for the stock.

Mar 30, 2016 by Michael Douglass

Better Dividend Stock: Retail Opportunity Investments Corp. vs. Realty Income

Two great dividend stocks, but only one can win.

Mar 26, 2016 by Michael Douglass

Is Exact Sciences Stock a Buy?

It's down over 70% in the last year. Time to buy?

Mar 8, 2016 by Michael Douglass

Better Big Biotech Stock: Biogen vs. Celgene

Biogen and Celgene are both great stocks. But there can be only one winner.

Mar 7, 2016 by Michael Douglass

Better Dividend Stock: Johnson & Johnson vs. Pfizer

Two big dividend stocks -- but only one is a buy.

Mar 6, 2016 by Michael Douglass

The Typical American Expects a Million-Dollar Retirement. How Do You Compare?

Do you really need a million dollars for retirement?

Feb 7, 2016 by Michael Douglass

Will Anthem Raise Its Dividend in 2016?

This is a key question for income investors, and the answer is less clear than the health insurer's history would suggest.

Feb 3, 2016 by Michael Douglass

5 Best Quotes From Anthem’s Earnings Call

Anthem's management explains how the business is doing and what we can expect from here.

Jan 31, 2016 by Michael Douglass

Here’s the Typical American’s Retirement Age. How Will You Compare?

And do you have a backup plan ready?

Jan 26, 2016 by Michael Douglass

Anthem Earnings: 3 Key Questions Management Should Answer

With earnings rapidly incoming, here's what you need to watch for when Anthem reports on Jan. 27.

Jan 23, 2016 by Michael Douglass

Gilead Takes a Page Out of Celgene's Playbook

Gilead's latest deal is reminiscent of Celgene's M&A strategy.

Jan 22, 2016 by Michael Douglass

Will 2016 Be Anthem’s Best Year Yet?

Maybe. But more importantly, what will 2016 mean for 2017 and 2018?

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services